PTG-300 in Subjects With Hereditary Hemochromatosis

Status Completed

Clinical Trial Summary

This study will be conducted at multiple sites and every patient will get treated with PTG-300. The objective of the study is to assess the effect of PTG-300 in treating adult hereditary hemochromatosis patients.

Clinical Trial Description

This study is a multicenter, open-label study. The objective of the study is to assess the effect of PTG-300 on transferrin saturation (TSAT) and serum iron in adult hereditary hemochromatosis patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04202965
Study type	Interventional
Source	Protagonist Therapeutics, Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	March 19, 2020
Completion date	February 15, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03395704` - A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis	Phase 2
Unknown status	`NCT01398644` - Erythrocytapheresis Versus Phlebotomy as Maintenance Therapy in Hereditary Hemochromatosis (HH) Patients	Phase 3
Terminated	`NCT05238207` - A Study to Evaluate BBI-001 in Hereditary Haemochromatosis (HH) Patients and Iron Deficient Volunteers	Phase 1
Enrolling by invitation	`NCT05742035` - Quality and Biologic Characteristics of Red Blood Concentrates Obtained From Individuals With Elevated Ferritin.	N/A
Terminated	`NCT03203850` - Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)	Phase 2
Completed	`NCT00068159` - Cardiac Function in Patients With Hereditary Hemochromatosis
Completed	`NCT00395629` - Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis	Phase 1/Phase 2
Completed	`NCT00440986` - Clinical Management of Hereditary Hemochromatosis: Phlebotomy vs. Erythrocytoapheresis	Phase 2/Phase 3